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Abbreviations 
AD  atopic dermatitis 
BCA  bicinchoninic acid 
cDNA  complementary deoxyribonucleic acid 
CE   cornified envelope 
EDC  epidermal differentiation complex 
FLG  filaggrin 
GM-CSF granulocyte-macrophage colony-stimulating factor 
IFNγ  interferon gamma 
ICD  irritant contact dermatitis 
IL-1ß  interleukin-1 beta 
IL-4  interleukin-4 
IL-12  interleukin-12 
IL-13  interleukin-13 
IVL  involucrin 
JAK  Janus kinase 
KLK7  kallikrein 7 
KRT14 keratin 14 
KO  knockout 
LOR  loricrin 
PBS  phosphate buffered saline 
PCR   polymerase chain reaction 
qRT-PCR quantitative real-time polymerase chain reaction 
SPINK5 serine peptidase inhibitor Kazal type 5 
SH2  Src homology domain 2 
STAT6 signal transducer and activator of transcription 6 
STAT6VT  STAT6 V547A/T548A mutation 
SC  stratum corneum 
TBS  tris buffered saline 
TEWL  transepidermal water loss 
TH1  T-helper Type 1 cells 
TH2  T-helper Type 2 cells 
TNFα  tumor necrosis factor alpha 
WT  wild-type 
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Introduction 
Atopic dermatitis (AD) is a pruritic, chronic inflammatory skin disease with a 
lifetime prevalence of 10-20% in children and 1-3% in adults, worldwide.  It is the most 
common cause of occupational skin disease in adults.  In the past three decades, 
prevalence of the disease has increased by two to three-fold in industrialized countries, 
with higher incidences in urban regions compared to rural regions (Leung & Bieber, 
2003).  A recent review has described how AD impacts both the child and immediate 
family (Sehra, et al., 2008).  The pruritic feature of AD can cause mental exhaustion, 
mood changes, lack of concentration in school or work, and an increase in parental and 
child morbidity.  The clinical features of AD include mild cases of erythema in localized 
areas of the body to acute lesions that appear as erythematous macules.  Lesions tend to 
occur on the cheeks, scalp and extensor areas of the arms and legs in infants, and in the 
flexural regions of the extremities in older children (Sehra, et al., 2008).  The 
pathogenesis of AD includes complex interactions between susceptibility genes, 
environment, and immunological factors (Leung, 2000).  Although recent studies have 
resulted in an enhanced understanding of the pathogenesis of AD, there is still a need for 
an improved elucidative animal model.   
The systemic immune response of AD involves an increase in blood serum IgE 
antibodies to nonpathogenic allergens and a decrease in interferon γ levels (IFNγ).  
Approximately 80% of children with AD will develop either allergic rhinitis or asthma 
(Leung & Bieber, 2003).  Biopsy samples from unaffected skin of patients with AD, 
compared to healthy, normal skin, show an increase in the number of TH2 cells that 
regulate interleukin-4 and interleukin-13 (IL-4, IL-13, respectively) (Hamid, et al., 1996).   
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Histologically, there are differences between acute and chronic atopic dermatitis.  
Acute AD lesions demonstrate focal parakeratosis, spongiosis of the epidermis, and 
inflammatory cell filtrates in the dermis made up of T-cells expressing IL-4 and IL-13, 
inflammatory dendritic epidermal cells, macrophages, eosinophils, mast cells, and 
antigen-presenting cells like Langerhans cells.  On the other hand, chronic AD shows a 
less pronounced dermal infiltrate and a significant reduction in IL-4 and IL-13 
expression.  Interleukin-5 (IL-5), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), interleukin-12 (IL-12), and IFNγ are also increased in comparison to the 
acute phase of AD and there is acanthosis (Dubrac, Schmuth, & Ebner).  The increase in 
IL-5 is generally seen during the transition from acute to chronic AD and may be 
responsible for prolonged eosinophil survival and function (Hamid, Boguniewicz, & 
Leung, 1994).   
Those with a history of AD are more prone to developing irritant contact 
dermatitis (ICD) of the hands.  The clinical result of ICD is inflammation caused by the 
release of proinflammatory cytokines from keratinocytes in response to chemical stimuli 
(Hogan, 1990).  Naive T-cells will differentiate into having either a Type 1 or Type 2 
helper T cell phenotype, (TH1 or TH2 respectively), depending on the source of antigen-
presenting cells.  Generally, the TH1 pathway is stimulated in response to intravesicular 
pathogens in response to infected macrophages.  On the other hand, TH2 cells are 
generated when basophils present antigen to the T cell receptor triggering antibody 
production in B-cells (Kaiko, Horvat, Beagley, & Hansbro, 2008).   
The skin is responsible for preventing loss of water from the body as well 
deterring the entry of environmental particulates.  The function of the epidermal 
3 
 
permeability barrier is characterized by the stratum corneum (SC); a complex made up of 
intracellular lipids, corneocytes, and a structural arrangement (Nielsen, 2000).  The SC 
has been likened to a brick wall, with the corneocytes acting as the brick and the lipid 
intracellular matrix as the cement.  During epidermal differentiation, there is a reduction 
in phospholipids but an increase in fatty acids and ceramides.  The final stages of 
epidermal differentiation are marked by the discharge of lipid-containing granules, or 
lamellar bodies, from the keratinocytes into the extracellular spaces in the upper granular 
layer, forming intercellular membrane bilayers (Loden, 1995). 
Skin transepidermal water loss (TEWL) is the rate at which water travels from the 
viable dermal and epidermal tissues through the SC to the external environment.  It is a 
widely accepted technique to evaluate the integrity of the SC and used to study skin 
barrier function (Loden, 1995).  TEWL (g/hm
2
) can be evaluated with a Tewameter® TM 
300 (Courage + Khazaka electronic GMB, Cologne, Germany).  It is important that 
certain considerations be taken into account, as published by the Standardization Group 
of the European Society of contact dermatitis, specifically room temperature and ambient 
humidity.  Air convection may interfere with the readings, so they should be taken in a 
draught protected area such as a hood (Pinnagoda, Tupker, Agner, & Serup, 1990).  
TEWL measurements can be used to monitor barrier repair as a function of time.  An 
increase in TEWL is an indicator of skin barrier dysfunction (Loden, 1995). 
Skin erythema is caused by dilation of the blood vessels with an infiltration of 
blood cells close to the skin surface and can be elicited by detergents, allergens or UV 
light.  Erythema is a major assessment in determining the irritation potential of a 
compound, and is typically determined by a visual score.  Certain factors can skew this 
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score including skin color, scorer subjectivity, and reproducibility between experiments 
(Ahmad Fadzil, Ihtatho, Mohd Affandi, & Hussein, 2009).  A noninvasive bioengineered 
tool that measures erythema is the Mexameter® MX18 (Courage + Khazaka electronic 
GMB, Cologne, Germany). 
Intact skin barrier is dependent on undisturbed epidermal differentiation which is 
coded for by a cluster of genes termed the epidermal differentiation complex (EDC).  
Variation within the EDC plays a major role in the pathogenesis of AD.  Microarray 
analysis of AD lesions have indicated altered gene expression of genes in the EDC, 
specifically downregulation of filament aggregating protein or filaggrin (FLG) and 
loricrin (LOR) (Hoffjan & Stemmler, 2007). 
The EDC spans 1.62 megabases on Chromosome 1q21.3 and contains about 50 
genes that are directly involved in the barrier function.  These genes encode proteins 
including (pro)filaggrin, involucrin, and loricrin. (Toulza, et al., 2007). 
FLG is the gene for the protein profilaggrin which is cleaved in the suprabasal 
keratinocytes in a complex biochemical cascade involving phosphatases and proteases 
into the active form filaggrin (FLG) (Koch, et al., 2000).  FLG has a high affinity for 
keratins and bundles the keratin intermediate filaments into packs (Koch, et al., 2000; 
Sehra, et al., 2008).  In the SC, FLG is eventually completely hydrolyzed freeing amino 
acids that are thought to contribute to water retention in the SC (Koch, et al., 2000).  
Loss-of-function mutations in FLG have been correlated to atopic dermatitis (Torma, 
Lindberg, & Berne, 2008).  In addition, the abnormal skin barrier seen in patients with a 
FLG null mutation and AD and TH2 polarization may be caused partly by an elevated 
allergen penetration through the skin (Leung, 2009).  On the other hand, overexpression 
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of murine filaggrin (Flg) in a transgenic model has been shown to accelerate the rate of 
barrier repair following chemical disruption (Presland, et al., 2004).  
IVL and LOR encode for involucrin (IVL) and loricrin (LOR), respectively, which 
have been shown to facilitate terminal differentiation of the epidermis and skin barrier 
formation (Kim, Leung, Boguniewicz, & Howell, 2008).  LOR is a major protein 
(constituting up to 70% of mass in mice) of the epidermal cornified cell envelope (CE) 
found in terminally differentiated epidermal cells.  The CE acts as a lamellar structure 
that is essential for the barrier function of the skin, preventing the loss of water and ions 
and providing protection from environmental factors (Koch, et al., 2000).  IVL is also 
found in the CE and acts as a scaffold to which other proteins become cross-linked (Kim, 
et al., 2008). 
KRT14 is responsible for encoding keratin, type 1 cytoskeletal 14, or keratin-14 
(KRT14), an intermediate filament protein that forms the structural framework of certain 
cells including those that make up skin, hair and nails ("Keratin, type 1 cytoskeletal 14," 
2010).  KRT14 is expressed in the basal layer of stratified squamous epithelia, 
specifically in the epidermis (Rosenberg, RayChaudhury, Shows, Le Beau, & Fuchs, 
1988). 
SPINK5 encodes a multidomain serine peptidase inhibitor Kazal type 5 that 
contains 15 potential inhibitory domains.  A recent study of Caucasian AD families 
showed that maternally derived alleles of the SPINK5 gene are associated with 
development of AD and asthma.  
The role of the innate immune system has been studied in the pathogenesis of AD 
(Niebuhr, Lutat, Sigel, & Werfel, 2009).  It is known that white blood cells, specifically 
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macrophages accumulate in the inflamed skin of both acute and chronic AD lesions 
(Kiekens, et al., 2001).  Macrophages differentiate from blood-derived monocytes in situ 
and are responsible for the phagocytosis of invading pathogens and dead cells, as well as 
the stimulation of cytokines.  The cytokines constitute a diverse group of soluble proteins 
and peptides that act as regulators of individual cells and tissues under both normal and 
pathological conditions.  Furthermore, they mediate intracellular interactions as well as 
processes occurring in the extracellular environment.  Cytokines behave similarly to 
hormones by acting at a systemic level by affecting inflammation.  However, they differ 
from classic hormones in that they act on a wider range of target cells, and are not 
produced by specialized cells that are organized in specialized glands.  They are 
classified as lymphokines, interferons, colony stimulating factors, and chemokines 
(Balkwill & Balkwill, 2000).  Macrophages are an important source of proinflammatory 
mediators including IL-1ß, TNFα, IL-6, CXCL8 (Bloemen, et al., 2007).   
Early events in atopic skin inflammation involve mechanical trauma and skin 
barrier disruption resulting in a rapid upregulation of the proinflammatory cytokines IL-
1α, IL-1ß, TNFα and GM-CSF (Homey, Steinhoff, Ruzicka, & Leung, 2006).  The 
relative contribution of an individual cytokine is dependent on the duration of the skin 
lesion, thus implicating both TH1 and TH2 cytokines in the pathogenesis of skin 
inflammation exhibited in AD (Werfel, 2009).  Studies have shown that IFNγ is 
upregulated in spontaneous or older lesions in AD (Grewe, et al., 1995).  AD patients 
have activated T-cells that express high levels of IFNγ that undergo apoptosis in 
circulation, skewing the immune response towards a TH2 phenotype.  This provides a 
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mechanism for the TH2 predominance seen in the circulation and in acute AD lesions 
(Akkoc, et al., 2008). 
The cytokine IL-4 plays a critical role in the pathosphysiology of asthma and 
allergic diseases.  The IL-4 pathway cascade is mediated through the activation of the 
latent transcription factor, signal transducer and activator of transcription 6 (STAT6).  
The STAT proteins consist of 750 to 800 amino acid residues and contain a Src 
homology 2 (SH2) domain and a carboxyl-terminal tyrosine phosphorylation site.  Seven 
STAT proteins have been identified.  STAT proteins require both tyrosine 
phosphorylation for dimerization and translocation to the nucleus and serine 
phosphorylation for transcriptional activation (Akira, 1999). 
STAT6 is a monomeric protein that is activated by the Jak/STAT pathway.  When 
IL-4 binds to its receptor, the Jaks phosphorylate tyrosine residues in the IL-4Rα and γc 
receptor chains, recruiting STAT6 to the IL-4Rα chain (Bruns, Schindler, & Kaplan, 
2003).  The STAT6 SH2 domain is integral to its interaction with the two 
phosphotyrosine-containing regions in IL-4.  As a result, STAT6 becomes 
phosphorylated on tyrosine 641 by Jak1 and/or Jak3 (Jak family of tyrosine kinases).  
The phosphorylated monomers then dimerize and migrate to the nucleus, where STAT6 
binds cis-acting elements to activate the transcription of IL-4 target genes (Daniel, 
Salvekar, & Schindler, 2000).  Previous experiments using STAT6 -deficient mice have 
shown that most IL-4 mediated functions are lost with the absence of STAT6 (Bruns, et 
al., 2003).  These losses of function include the inability to regulate Ig isotype expression 
by promoting a class switch to IgE and IgG1 in antigen-activated B cells.  In addition, 
there is no induction of IL-4-induced cell surface markers, and lymphocytes have 
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impaired proliferative responses to IL-4.  Finally, the STAT6-deficient mice cannot 
promote the differentiation of naïve CD4
+
 T-cells into the TH2 phenotype (Bruns, et al., 
2003).   
Mice with an activating mutation in STAT6, known as STAT6VT, constitutively 
express STAT6 in T-cells.  The difference between STAT6VT and wild-type (WT) mice 
is that the mutant contains two residue substitutions at positions V625A and T626A in the 
SH2 domain.  The STAT6VT is constitutively phosphorylated on the critical tyrosine 
residue, Y641, and transcriptionally active in the absence of IL-4.  The conformational 
change in the protein caused by the mutation hinders the association of STAT6VT with 
the unphosphorylated IL-4R chains (Bruns, et al., 2003).  
The ability of the constitutively active STAT6 to mimic the IL-4 activated 
functions in vivo was evaluated by generating a transgenic mouse that expressed 
STAT6VT only in lymphoid tissues; it was engineered using a C-terminal FLAG tag.  
The vector containing the STAT6VT cDNA was digested with EcoRI, and the fragment 
was cloned into VACD2, a plasmid containing the CD2 locus control region (LCR).  
Next, the CD2: STAT6VT vector was digested with KpnI and XbaI, resulting in a 15.7 kb 
fragment that was purified and used to generate the transgenic mice.  The resulting mice 
contain a conformational change in the STAT6 protein that allows for it to be 
phosphorylated, bind DNA and activate transcription independent of IL-4 stimulation.  
The STAT6VT transgenic mice have altered lymphocytic behavior.  The expression of 
STAT6VT in the B lymphocytes causes increased expression of IL-4 related inducibility 
and increased production of IgG1 and IgE, but no activation of the B lymphocytes.  The 
same STAT6VT expression in the T lymphocytes results in T cell differentiation towards 
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a TH2 phenotype (Daniel, et al., 2000).  The STAT6VT transgenic mice develop AD 
symptoms under specific pathogen-free conditions and do not require overexpression of 
effectors in the skin.   
Sodium lauryl sulfate (SLS), an anionic detergent, is a common ingredient found 
in soaps, shampoos, and various other skin care products.  It has been shown to trigger a 
prolonged barrier disruption of the skin that lasts up to a week following a single 24-hour 
application.  SLS is commonly used in studies involving skin barrier damage (Patil, 
Singh, Sarasour, & Maibach, 1995; Torma, et al., 2008).  The underlying molecular 
mechanisms to explain barrier repair after chemical disruption of the skin are currently 
limited, although it is known that altered keratinocyte differentiation may occur (Ponec & 
Kempenaar, 1995).  SLS penetrates the skin to a depth of 5-6mm below the site of 
application in a hairless rat model (Patil, Singh, Sarasour, et al., 1995).  The radial spread 
of SLS can elicit increased TEWL and decreased skin capacitance in areas adjacent to the 
application sites, as far as approximately 0.75cm away (Patil, Singh, & Maibach, 1995).  
It appears that SLS acts in a time-and-dose dependent manner to disrupt the barrier 
function (Nielsen, 2000).  The goal of the present studies was to assess the effects of 
topical SLS on skin in normal and STAT6VT mice.  Our hypothesis is that treatment of 
STAT6VT mice, at a young age where they have no clinical abnormalities, with SLS will 
result in an increased barrier disruption in comparison to WT mice.  Our preliminary data 
suggests significant differences between the STAT6VT transgenic mice from WT 
littermate controls treated with SLS.  These findings correlate with evidence that there are 
abnormalities in the barrier function between these mice (Sehra, et al., 2010). 
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Polymerase chain reaction (PCR) is a standard laboratory technique that amplifies 
a specific DNA sequence in vitro (Mullis, 1990).  Quantitative real-time PCR (qRT-PCR) 
is used to determine the copy number of target DNA in a particular sample.  Taqman 
PCR is a probe-based system that uses a fluorogenic probe containing a reporter 
fluorescent dye and a quencher dye to provide a fast and reliable method for semi-
quantitative analysis of gene expression (Medhurst, et al., 2000).  Cytokine analysis of 
several analytes can be done simultaneously using an array system based on Luminex® 
xMAP technology.  This method is based on flowmetric analysis of beads acting as a 
solid support for individual reactions using a common fluorophore reporter.  The 
measurement of an array of cytokines is important for studying inflammatory diseases 
and diseases of unknown etiology (Skogstrand, et al., 2005).  The bicinchoninic acid 
(BCA) assay is a colorimetric assay used to quantify the amount of protein in a sample 
(Sapan, Lundblad, & Price, 1999).  
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Materials and Methods 
Wild-type (WT) and STAT6VT transgenic mice 
The STAT6VT transgenic mice have been generously provided by Dr. Mark 
Kaplan at Indiana University School of Medicine, Indianapolis, IN for our breeding 
purposes.  These heterozygous mice were bred with C57BL/6 mice (Harlan Laboratories, 
Indianapolis, IN) to generate additional transgenic mice and WT controls.  All mice were 
maintained in standard microisolator cages under a simulated 12-hour day/night cycle 
and were fed and watered ad libitum.  All animal experiments were in compliance with 
and approved by the Indiana University School of Medicine Animal Care and Use 
Committee.   
 
Mouse Genotyping using a Taq Polymerase 
PCR-quality mouse genomic DNA was prepared by using a hot sodium hydroxide 
and tris (HotSHOT) method.  Mouse tail snips (0.2-0.5 cm long) were collected into 0.5 
ml PCR tubes and placed on ice.  If lysis could not be done immediately, the tails were 
placed at -20
o
C for storage.  The stock reagents include an alkaline lysis reagent prepared 
with 25 mM NaOH, 0.2 mM disodium EDTA (pH=12) dissolved in water without 
adjusting the pH; and a neutralizing reagent of 40 mM Tris-HCl (pH=5) also dissolved in 
water without adjusting the pH.  Next, 0.75 µl of the alkaline lysis was added to the tail 
snip, heated to 95
o
C for 30 minutes, and cooled to 4
o
C.  Then 0.75 µl of neutralizing 
reagent was added, spun down and either used immediately or the supernatant was stored 
at -20
o
C (Truett, et al., 2000).  The PCR conditions to screen for the STAT6VT transgene 
(5′ sequence: gcctaccatggtgccttcttatg, 3′ sequence: tatgcttgtcatcgtcgtccttgtagtcac) 
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consisted of a 1 minute denaturation step at 94
o
C and 34 cycles of 94
o
C for 20 s, 58
o
C for 
30 s, and 72
o
C for 45 s. 
 
Induction of chronic irritation and biophysical measurements 
The development of chronic atopic symptoms in mice was induced by treating the 
intact dorsal skin of both STAT6VT and WT sibling controls with 0.1 ml of a 5% 
aqueous solution of sodium lauryl sulfate (BioRad Laboratories Inc., Hercules, CA) and 
distilled water (vehicle).  The animals were kept in clean rooms with controlled 
temperature (22±2
o
C) and humidity (35-40%), and lit with a 12-hour on/off cycle.  
Female mice were used in all experiments unless otherwise indicated.  Approximately 
two to three mice were assigned to each of the following four groups: STAT6VT 
Vehicle, WT Vehicle, STAT6VT SLS and WT SLS during each of the three experiment 
trials.  The SLS was applied in a regime of three sets of daily exposure for six 
consecutive exposures followed by a 14-day period with no application.  On Day 0, the 
mice were briefly anesthetized with ketamine/xylazine (80/10 µg/kg body weight) 
intraperitoneally and the dorsal hair was shaved.  Twenty-four hours later, baseline 
transepidermal water loss (TEWL, g/hm
2
) measurements were taken with a Multi Probe 
Adapter (MPA) fitted with a TM300 Tewameter (Courage + Khazaka, Cologne, 
Germany), and 0.1 ml 5% SLS was applied topically to irritate the skin.  Subsequent 
TEWL readings were taken daily during the application time course, and every other day 
during non-application days.  The same sample size of WT sibling control mice were 
treated similarly.  A final six day treatment period of 10% SLS was done.  The accepted 
practice of TEWL measurement using an open chamber system is based on assessing the 
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vapor pressure that builds up inside the probe tunnel when it is placed on the skin surface.  
To minimize the possible errors of this method caused by fluctuations in the relative 
humidity and skin surface temperature, standard procedures were followed.  All 
measurements were performed at standard laboratory conditions (temperature of 20-25
o
C 
and humidity of 30-40%).  The probe was applied so that it was in full contact on the 
dorsal median and the probe temperature was given time to acclimate to the skin 
temperature (approximately 20 s).  The change in TEWL for each mouse was compared 
to each individual mouse’s baseline value and the fold increase was plotted. 
 
Tissue Processing 
The dorsal skin of age-matched mice (STAT6VT and WT) that was treated with 
SLS or water was harvested within 72 hours following the final treatment.  The skin 
tissue was processed for each of the following: tissue was harvested and preserved in 
RNAlater RNA Stabilization Reagent (Qiagen, Valencia, CA) for qRT-PCR analysis, 7 
mm skin biopsies were harvested to assess cytokine levels, and 0.5 cm
2
 skin sections 
were harvested and fixed in 10% neutral buffered formalin for 1.5 hours for paraffin-
embedding and histologic assessment and immunohistochemical analysis.  The remaining 
tissue was snap-frozen in liquid nitrogen and stored at -80
o
C.  
 
Immunohistochemistry for Ki-67 and quantification of positive staining 
Mouse dorsal skin sections were formalin-fixed for 1.5 hours and changed to 70% 
EtOH, trimmed and placed in cassettes for further processing and embedding.  For Ki-67 
immunolabeling, standard deparaffinization and hydration were performed followed by 
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heat-induced antigen retrieval using 10 mM citrate buffer, pH 6.0 for 20 min.  All 
reagents were purchased from DAKO, Carpinteria, CA unless otherwise noted.  Sections 
were incubated with 3% hydrogen peroxide for 10 min at room temperature.  Sections 
were washed with TBS followed by incubation with Ki-67 (SP6) (Thermo Scientific).  
The sections were then washed and incubated with Envision+ System-HRP (DAB) for 
use with rabbit primary antibodies for 30 min at room temperature. DAB+ was used for 
substrate detection.  Sections were then counterstained and mounted.  All images taken 
with a Nikon Eclipse E400 microscope (Nikon Corp., Melville, NY) at 200X 
magnification were saved as .tiff files and subjected to a background subtraction in NIH 
Image J.  For the background subtraction, the light background, separate colors, and 
sliding parabaloid functions were checked.  The images were opened in Metamorph Meta 
Imaging Series 7.5 (Molecular Devices, Downington, PA).  In Metamorph, the epidermis 
was selected using the region drawing tool and the images were color separated into blue, 
red, and green images.  For thresholding on Ki-67 positive cells as a percentage of the 
total epidermal area, the blue image was utilized.  Total epidermal nuclei were estimated 
by thresholding on a grayscale image in Metamorph.  All images were analyzed using the 
same threshold settings for K-i67 and total nuclei.  Results are shown as the ratio of Ki-
67 positive thresholding relative to total epidermal nuclei. 
 
Quantification of epidermal thickness by IHC 
Changes in overall morphology were visualized following hematoxylin and eosin 
(H&E) staining of paraffin-embedded tissue samples.  Epidermal thickness was measured 
by an optical micrometer in a blinded manner using a Nikon Eclipse E400 microscope at 
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200X total magnification.  Measurements (µm) were taken from the base of the stratum 
corneum to the basement membrane of the inter-rete ridges along the entire length of 
each section, in 3 random fields in an observer-blinded manner for each condition. 
 
Total RNA extraction and cDNA synthesis 
To quantify the relative gene expression for each mouse, the skin tissue preserved 
in RNAlater was first weighed (<30mg) and total RNA was isolated using the RNeasy 
Fibrous Mini Kit (QIAGEN Inc, Valencia, CA).  The skin tissue was disrupted and 
homogenized in Buffer RLT with ß-Mercaptoethanol and a stainless steel bead (5 mm 
mean diameter) with a TissueLyser (QIAGEN Inc, Valencia, CA) for three repeated 
bursts of 2 min at 20 Hz.  After a proteinase K digestion step, DNase was used to remove 
any traces of DNA that may copurify with the total RNA.  The eluate was collected and 
the concentration of total RNA(1 µl) was determined by using a NanoDrop 2000 UV-Vis 
spectrophotometer (Thermo Scientific, Wilmington, DE) at 280 nm, and all samples were 
blanked with 1 µl of RNase-free water.  RNA (0.85 µg) was reverse-transcribed in a 20 
µl reaction containing Random Primers (50 ng/µl: Invitrogen, Carlsbad, CA), dNTP (10 
mmol/L; Invitrogen) with a 5 min denaturation step at 65
o
C; then 10X First Strand RT 
buffer (Invitrogen), DTT (0.1 mol/L; Invitrogen), Superscript III RT enzyme (200 U/µl; 
Invitrogen) for 10 min at 25
o
C, 50 min at 50
o
C and 5 min at 85
o
C; and RNase H 
(Invitrogen) for 20 min at 37
o
C.  The cDNA was either stored at -20
o
C or used for qRT-
PCR immediately. 
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Quantitative real-time PCR 
Relative gene expression was studied by qRT-PCR in a 10 µl volume reaction in 
MicroAmp® 96-well reaction optical tubes in the 7900HT Fast Sequence Detection 
System (Applied Biosystems, Stockholm, Sweden).  cDNA was used as template (0.85 
µg total RNA) along with a dual-labeled fluorogenic probe method using Taqman 
primers.  All primers and probes for murine genes were purchased from Applied 
Biosystems.  Relative gene expression levels were calculated using the ΔΔCT method.  
Quantities of all targets in each sample were normalized to the corresponding Krt14 in 
the skin biopsies.   
 
Cytokine analysis 
Punch biopsies of 7 mm diameter were taken from mouse dorsal skin that had 
been challenged with SLS or vehicle and stored at -80
o
C.  The skin was minced on a 
glass plate using a razor blade and homogenized on ice in 800 µl cold PBS containing 
protease inhibitor cocktail and 0.1% Triton X-100 (Sigma Aldrich, St Louis, MO).  The 
samples were centrifuged at 1000 RPM for 10 min at 4
o
C and the supernatant was used 
for cytokine analysis.  Cytokine and chemokine analysis for murine GM-CSF, IFNγ, IL-
10, IL-12 (p70), IL-13, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, MCP-1, and TNFα was done 
using the MILLIPLEX™ MAP cytokine and chemokine panel, based on the Luminex 
xMAP platform (Millipore, Billerica, MA) at Johnson & Johnson, Skillman, NJ. 
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Normalization of protein levels 
Cytokine levels were normalized to total protein levels determined by a Pierce 
BCA protein assay kit (Thermo Scientific, Rockford, IL.).  10 µl of all standards and 
samples were diluted in 200 µl of the BCA working reagent (50:1, Reagent A: B) to yield 
a sample to working ratio of 1:20) in a microplate.  The standards used were known 
concentrations of bovine serum albumin (BSA) diluted in the same homogenization 
solution given above.  Plate was covered and incubated at 37
o
C for 30 min.  The 
absorbance for both the standards and the samples were read at 562 nm in a Beckman 
spectrophotometer blanked with 800 µl cold PBS containing protease inhibitor cocktail 
and 0.1% Triton X-100 and 200 µl of BCA working reagent.  The absorbance values for 
the standards were plotted using Microsoft Excel for a linear regression fit to generate a 
standard curve from which the protein concentration of experimental standards could be 
determined. 
 
Statistics 
Statistical analysis was conducted using Graph Pad Prism, version 5.0 (San 
Diego, CA).  Statistical differences between groups were determined using the student t-
test with significant differences conferred when p<0.05.  In cases where multiple groups 
were compared, data were analyzed by a one-way analysis of variance (ANOVA).  
Where the direction of change was known, a one-tailed student t-test was employed. 
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Results 
Chronic irritant treatment of STAT6VT mice augmented barrier disruption 
Initially, we assessed whether the STAT6VT transgenic mice exhibited baseline 
differences in barrier function by measuring TEWL using the Tewameter® TM 300.  The 
baseline TEWL levels were similar in C57BL/6 controls versus STAT6VT transgenic 
mice (data not shown).  Next, we assessed the effect of chronic irritant SLS by two 
groups of six daily applications separated by a 14-day interval.  As shown in Fig. 1, the 
fold increase in TEWL (plotted as TEWLgiven day / TEWLbaseline) was increased in 
STAT6VT mice repeatedly treated with SLS compared to WT mice similarly treated, 
with significant (* p<0.05) differences between the two groups were seen on days 10, 12, 
24, 26, 52, 54, and 57.  Furthermore, TEWL was increased in STAT6VT mice during 
each of the application periods, whereas the reactions seen in the WT were not as 
pronounced.  Next, we assessed whether a higher concentration of SLS would elicit a 
greater increase in TEWL, so we applied a 10% SLS solution to the mouse dorsum.  It 
should be noted that the fold increase in TEWL does not appear to be further increased 
with the higher SLS dose.  The chronic SLS treatment resulted in irritation of the mouse 
dorsal skin as shown in Fig. 2A.  Visually, the STAT6VT transgenic mice exhibit 
increased erythema and excoriations compared to WT littermate controls which did not 
develop dermatitis.  As shown in Fig. 2B, the change in TEWL (TEWLendpoint - 
TEWLbaseline) was significantly increased in both STAT6VT and WT mice following 
repeated SLS applications compared to controls.   
Concurrently with the tewameter studies, we assessed the irritation potential of 
SLS on the STAT6VT transgenic and WT mice by measuring erythema with the 
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Mexameter® MX18.  The change in erythema (erythemaendpoint - erythemabaseline) in both 
the WT and STAT6VT transgenic mice treated with SLS was significantly augmented as 
shown in Fig. 2C compared to the vehicle control groups (data not shown).  However, 
there were no differences in the mexameter readings in SLS treated STAT6VT compared 
to WT mice.  The present studies indicate that the STAT6VT transgenic murine model 
exhibits increased barrier disruption following chronic treatment with SLS.   
 
Effects of SLS on inflammation 
Previous studies have shown that the STAT6VT transgenic mice have increased 
scratching behavior that result in dermatitic plaques with alopecia on the face, dorsum 
and other areas (Sehra, et al., 2010).  We therefore examined the effect of SLS on the 
inflammatory response in murine skin.  As shown in Fig. 3, histological evaluation 
revealed a marked influx of inflammatory cells in SLS-treated STAT6VT transgenic 
mice compared to similarly treated WT littermate controls.  Importantly, the vehicle-
treated STAT6VT mice exhibited low-grade inflammatory cell infiltration of the dermal 
region; whereas, the SLS treatment resulted in more severe inflammation. 
 
Repeated SLS treatment augments hyperproliferation as determined by epidermal 
thickness (hyperplasia) and Ki-67 immunolabeling 
Previous studies have provided evidence that topical acetone treatment or tape 
stripping induces epidermal hyperplasia in mice (Denda, et al., 1996).  The degree of the 
epidermal hyperplasia correlated with the duration of the treatment period.  In addition, 
the hyperplasia was attributed to increased cell proliferation.  In our studies, we were 
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interested in examining the effect of SLS on the STAT6VT transgenic mice on these 
responses.  First, we evaluated the ability of SLS to induce hyperplasia by assessing 
epidermal thickening (Fig. 4A).  Quantitative epidermal measurements indicate a marked 
increase in STAT6VT transgenic mice treated chronically with SLS (* p<0.05).  No 
differences are noted between the STAT6VT transgenic mice treated with vehicle or the 
WT mice treated with SLS or vehicle.   
Next, we assessed whether the increased epidermal thickness in SLS-treated 
STAT6VT mice was due to increased cellular proliferation.  Ki-67 is a nuclear protein 
that provides a reliable method to evaluate the growth fraction of cells during late S, M 
and G2 phases (Gerdes, et al., 1984).  As shown in Fig. 4B, quantification of Ki-67 
following chronic SLS treatment indicated that there is a greater proliferative effect in the 
SLS-treated STAT6VT.  This trend is consistent with that of the epidermal thickening 
suggesting that the increased epidermal thickening correlates with proliferation.   
 
EDC gene expression is altered due to skin barrier disruption by SLS 
Our next studies were designed to assess the role of EDC genes in the enhanced 
SLS-mediated barrier disruption found in STAT6VT mice.  Thus, the expression of 
specific EDC genes in skin of vehicle and SLS-treated mice was analyzed through qRT-
PCR.  As shown in Fig. 5A, although the expression of Flg appears greater in STAT6VT 
transgenic mice as well as in the WT mice compared to control mice, the differences did 
not achieve statistical significance.  There are also no obvious changes in expression of 
Ivl and Klk7 (Fig. 5B and 5D, respectively) compared to controls.  On the other hand, a 
major reduction is seen in the Lor expression in both the STAT6VT vehicle and WT 
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SLS-treated mice compared to WT vehicle-treated littermate controls in Fig. 5C (* 
p<0.05).  Similarly, the Spink5 mRNA expression (Fig. 5E) is downregulated in 
STAT6VT vehicle and SLS-treated mice compared to WT vehicle-treated littermate 
controls (**p<0.01).  These studies indicate that the STAT6VT transgene may contribute 
to a downregulation of Lor and Spink5 gene expression following SLS treatment. 
 
Gene expression and protein levels of inflammatory murine cytokines are altered 
following exposure to SLS 
Previous studies have implicated TH2 immune response in acute, and more mixed 
TH1-TH2 immune response in chronic AD (Akdis, et al., 2003; Akkoc, et al., 2008).  Our 
next studies were designed to characterize the inflammatory cytokines in our murine 
model.  As shown in Fig. 6A, Il-13 gene expression is upregulated in SLS-treated WT 
mice compared to vehicle-treated WT controls.  However, as seen in Fig. 6B, Il-1ß gene 
expression is significantly downregulated in SLS-induced WT and STAT6VT mice 
compared to vehicle-treated WT mice (* p<0.05).  Similarly, Tnfα gene expression (Fig. 
6C) is significantly (* p<0.05) reduced in the SLS-treated STAT6VT mice compared to 
both vehicle and SLS-treated WT mice.  There are no obvious changes in mRNA 
expression of Ifnγ and Mcp-1 (Fig. 6D and 6E, respectively) compared to controls.   
Next, we measured protein expression level to attempt to correlate with cytokine 
gene expression.  Table 1 provides an overview of the protein expression of various 
cytokines normalized to total protein (represented as pg/mL cytokine per µg protein).  
Previous studies have reported that AD patients have an increased activation and 
apoptosis of high IFNγ producing TH1 cells which may result in a predominant TH2 
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profile (Akkoc, et al., 2008).  Our studies show that IFNγ was significantly upregulated in 
SLS-treated STAT6VT and WT mice compared to littermate controls, but the gene 
expression results were not statistically significant.   
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Discussion 
Development of an irritant contact dermatitis by repeated applications of SLS in 
STAT6VT mice 
In this study, we were interested in whether the STAT6VT transgenic mouse 
would be an appropriate model to study irritant contact skin inflammation, and compare a 
normal mouse versus a mouse with immunological abnormalities associated with AD.  
Since approximately 40% of STAT6VT transgenic mice develop spontaneous skin 
inflammation characteristic of AD, we wanted to assess the effects of barrier disruption in 
this model.  As a means to this end, we used previously described methods to induce 
irritant-induced dermatitis (De Jongh, et al., 2006; Torma, et al., 2008).  In regards to 
permeability barrier homeostasis, we used biophysical parameters to measure barrier 
function.  TEWL measurements were elevated in the transgenic model compared to 
controls with significance observed on treatment days and at the conclusion of the 
chronic phase.  The STAT6VT transgenic mouse has impairment in barrier recovery 
following skin irritation as evidenced by a marked increase in the difference for both 
TEWL and erythema at the study endpoint compared to baseline.  Interestingly, the SLS-
treated WT mice seemed to have decreased responses, or hardening after multiple 
treatments.  However, this effect was not seen in the STAT6VT transgenic mice.  Of 
particular note, the TEWL of the WT mice returned to baseline levels during the interval 
period between treatments, unlike the STAT6VT transgenic mice. 
Our study found that there were significant differences in the TEWL and 
erythema responses amongst the SLS-treated STAT6VT transgenic mice.  A possible 
explanation is the induction of hair growth in the experimental (SLS) groups, a finding 
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not observed in the control groups.  Of note, a study by another group showed visible 
acceleration of hair growth on SLS-treated skin at three weeks from the start of treatment 
(Li, Fiedler, & Kumar, 1999).  SLS permeability is impacted by accelerated hair growth 
during a long-term study.  Another difficulty of using a murine model in the C57BL/6 
background was that a completely accurate erythema visual score was limited due to the 
melanin content of the murine skin.  For future studies, we have bred the STAT6VT 
transgenic mouse into a SKH1-Hr 
hr
 (hairless, albino) background which is currently 
used for research studies in skin inflammation, wound healing, and safety and efficacy 
testing.  This model should allow for better penetration of a topical irritant and easier 
visualization of skin plaques and lesions that form. 
Epidermal thickness and active proliferation data supports the inflammatory 
infiltration in the STAT6VT transgenic mouse treated with a topical irritant resulting in a 
hyperproliferative dermatitis.  Another group has similarly shown that irritant skin 
reactions caused from repeated applications of SLS result in increased epidermal 
thickness (Anderson, Sundberg, & Groth, 1986).  Previous and current studies by our lab 
have shown that STAT6VT murine ear tissue, even in mice without obvious
 
lesions, 
exhibits a marked thickening of the dermis and epidermis
 
with cellular infiltration of 
eosinophils and lymphocytes (Sehra, et al., 2008).  A poor correlation was found between 
hyperplasia and increased TEWL in our murine model (data not shown) indicating the 
complex nature of barrier disruption.   
It has been previously reported that Flg mRNA expression is significantly 
reduced in older (>4 months of age) STAT6VT transgenic mice compared to WT 
controls (Sehra, et al., 2008).  Contrarily, our present studies found that the Flg levels 
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were increased, but these differences did not achieve statistical significance.  This may be 
in part due to the fact that SLS treatment was started in 10- to 14-week old STAT6VT 
and WT mice.  The SLS-induced irritation introduced at this age may have affected Flg 
gene expression.  Others have shown an induction in profilaggrin mRNA expression in 
humans four days after exposure to 1% SLS; although there was an initial reduction six 
hours postexposure (Torma, et al., 2008).  Further studies in keratinocytes overexpressing 
filaggrin have suggested an addition role for filaggrin.  This group reported that filaggrin 
disrupted actin microfilament distribution, altered the cell shape, and disrupted the 
distribution of desmosome proteins that occurs at the granular to cornified cell transition 
that happens during terminal keratinocyte differentiation (Presland, Kuechle, Lewis, 
Fleckman, & Dale, 2001).  Previous studies by another group show that filaggrin 
expression is increased in lesional skin from patients with AD without the 2282del4 FLG 
mutation  (Howell, et al., 2009), which may account for the results seen in this study.   
Our findings indicate that Lor gene expression is diminished in the STAT6VT 
transgenic mice (Kim, et al., 2008; Sehra, et al., 2008).  Interestingly, the WT mice 
treated with SLS also have a marked decrease in Lor mRNA expression.  However, these 
mice did not develop visual or biophysical (augemented TEWL and erythema) signs of 
dermatitis which further suggests that the downregulation of loricrin is not the only 
contributing factor of barrier function.  Of interest, it has been reported that loricrin-
deficient mice are prone to desquamation but not to increases in TEWL (Koch, et al., 
2000).   
The cytokine multiplex studies indicate a potential, although not significant, 
increase in TH2 cytokines including IL-1ß and IL-5 in the STAT6VT vehicle and SLS 
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groups.  As an established model of AD arising from
 
T-cell specific expression of an 
active STAT6, our transgenic mice are predisposed to a TH2 response.  As a coordinator 
of eosinophilic-based inflammatory responses, an increase in IL-5 would provide a link 
between barrier disruption and allergic inflammation.  Of interest, the T-regulatory (T-
reg) cytokine IL-10 appears to be reduced in STAT6VT transgenic mice compared to 
similarly SLS-treated WT mice.  Previous work has shown that the augmentation in IL-
10, produced primarily by monocytes and partly by lymphocytes and having pleiotropic 
effects in immunoregulation and inflammation, may provide one explanation for the 
downregulation of TH1 cytokine expression (Moore, de Waal Malefyt, Coffman, & 
O'Garra, 2001).  Our studies also show that IFNγ was significantly upregulated in SLS-
treated STAT6VT and WT mice compared to littermate controls.  However, the mRNA 
expression results were not statistically significant possibly explained by previous studies 
showing that AD patients have higher levels of activation and apoptosis of IFNγ 
expressing TH1 cells in circulation, skewing the immune response towards a TH2 
phenotype (Akkoc, et al., 2008).  The lack of further significant findings in cytokine 
protein expression may partly be due to incompletely homogenizing the murine skin 
tissue.  
Our findings further corroborate the complexity of the molecular mechanisms 
towards a TH2 bias at play in atopic diseases.  The STAT6VT transgenic mice 
spontaneously develop skin inflammation and have abnormalities in EDC genes as well 
as abnormal barrier function.  As a result, these mice provide evidence that there is a link 
between allergic inflammation and permeability barrier homeostasis.  The STAT6VT 
transgenic murine model is clinically relevant because it provides a platform involving 
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the complex interactions between susceptibility genes, pharmacological abnormalities 
and immunological abnormalities.  Consequently, our murine model can be used in future 
studies such as the determination the point at which barrier function can no longer be 
repaired.  
 
 
 
Fig. 1  TEWL is augmented in STAT6VT transgenic mice with repeated SLS irritation.  STAT6VT transgenic and WT 
C57BL/6 sibling controls were treated for 3 six-day periods with 5% SLS followed by a single six-day period of 10% SLS.  
TEWL(g/hm
2
) measurements were taken prior to the application of the topical irritant.  The dates of topical irritation were: 
Days 1-6, 20-25, 39-44 and 48-53, as indicated.  STAT6VT mice show a marked increase in TEWL (g/hm
2
) during each of the 
application periods as compared to WT mice.  Results are the mean ± SEM from samples of 5-8 mice.  Results significantly 
different from WT, * p<0.05, ** p<0.01.   
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Fig. 2  Barrier disruption in WT versus STAT6VT transgenic 
mice following repeated SLS treatment.  STAT6VT and littermate 
controls (10-14 weeks) were shaved and TEWL and erythema were 
measured with a Multi Probe Adapter fitted with either a 
Tewameter® TM 300 or Mexameter® MX18 (Courage-Khazaka, 
Germany) during the chronic treatment period.  All measurements 
were taken prior to the application of the topical irritant.  Results are 
the mean ± SEM from samples of 5-8 mice.  A, Photographs of 
STAT6VT transgenic mice and littermate controls showing areas 
affected by skin inflammation.  B, Barrier function is disrupted 
following chronic irritant treatment. C, Erythema is increased in 
STAT6VT and littermates following SLS treatment.  In both B and C, 
results significantly different from WT, * p<0.05, ** p<0.01, † 
represents conditions compared to WT control, †† represents 
conditions compared to STAT6VT control.  
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Fig. 3  STAT6VT mice exhibit enhanced inflammation in the shaved dorsal epidermis following repetitive SLS 
application.  The dorsal epidermis of STAT6VT and littermate controls were chronically treated with vehicle or 5% SLS.  A 
portion of the dorsal epidermis was fixed in 10% buffered formalin and H&E stained slides were produced.  The images show 
inflammatory infiltration in STAT6VT mice, 400X.  
3
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Fig. 4  STAT6VT transgenic mice feature augmented hyperplasia and active proliferation following repeated SLS 
treatment.  The dorsal epidermis of STAT6VT and littermate controls were chronically treated with vehicle or 5% SLS.  
Results are the mean ± SEM from samples of 5-8 mice.  A, STAT6VT transgenic mice have augmented epidermal thickness.  
A portion of the dorsal epidermis was excised, fixed in 10% buffered formalin, and paraffin-embedded.  Epidermal thickness 
was then measured in H&E stained slides by light microscopy using a micrometer.  B, Paraffin-embedded mouse skin excised 
were subjected to immunohistochemical analysis of Ki-67 as detailed in the methods sections. For each treatment group, Ki-67 
positive cells were counted with MetaMorph Premium Offline software in 5 randomly chosen high power fields.  In both A & 
B, slides were blinded prior to analysis, and results significantly different from WT, * p<0.05. 
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Fig. 5  Effect of SLS on EDC genes in WT versus STAT6VT transgenic mice. A-E, RNA was isolated from skin of WT and 
STAT6VT transgenic mice before analysis of EDC mRNA using qPCR.  Each sample for qPCR was run in triplicate. Results 
are the mean ± SEM from samples of 5-8 mice.  Bar graphs represent the relative expression normalized to expression of 
Krt14. Results significantly different from WT, * p<0.05; ** p<0.01, † represents conditions compared to WT vehicle control.  
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Fig. 6  Effect of SLS on inflammatory cytokine gene expression in WT versus STAT6VT transgenic mice. A-E, RNA was 
isolated from skin of WT and STAT6VT transgenic mice before analysis of inflammatory murine cytokine mRNA using 
qPCR.  Each sample for qPCR was run in triplicate.  Results are the mean ± SEM from samples of 4-7 mice.  Bar graphs 
represent the relative expression normalized to expression of beta microglobulin. Results significantly different from WT, 
*p<0.05, † represents conditions compared to WT vehicle control.  
3
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Table 1  Inflammatory cytokine protein expression in STAT6VT transgenic mice treated with repeated SLS 
  WT VEH STAT6VT VEH WT SLS STAT6VT SLS 
GM-CSF 1.230 ± 0.490 1.862 ± 0.604 1.508 ± 0.763 1.984 ± 1.155 
                          
IL-1ß 1.413 ± 0.533 1.764 ± 0.527 1.922 ± 0.800 2.699 ± 2.476 
                          
IL-2 0.292 ± 0.063 0.328 ± 0.104 0.409 ± 0.207 0.445 ± 0.155 
                          
IL-5 1.202     1.474 ± 0.522 1.389 ± 0.727 1.568 ± 0.394 
                          
IL-6 0.394 ± 0.240 0.413 ± 0.094 0.781 ± 0.630 1.272 ± 1.420 
                          
IL-10 ND     0.018     0.336 ± 0.356 0.264 ± 0.224 
                          
IL-13 0.318 ± 0.154 0.309 ± 0.103 0.498 ± 0.225 0.460 ± 0.179 
                          
IL-12 0.135 ± 0.064 0.165 ± 0.043 0.220 ± 0.100 0.289 ± 0.075 
                          
IFNγ 0.346 ± 0.157 0.526 ± 0.641 1.061 ± 0.430 * † 1.170 ± 0.681 * † 
                          
MCP-1 0.967 ± 0.276 1.497 ± 0.304 1.303 ± 0.487 1.525 ± 0.609 
Cytokine analysis was done using the MILLIPLEX™ MAP system and total protein was normalized to BCA assay as 
described in the methods section.  Results significantly different from WT, *p<0.05, † represents conditions compared to WT 
vehicle control. 
3
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